^
Association details:
| Biomarker: | MSH2 deletion |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | temozolomide (DNA synthesis inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Reduction or loss of Msh2 confers resistance to temozolomide in glioblastoma
Published date:
03/09/2022
Excerpt:
In addition, our results indicate Msh2 deficiency increases the malignancy of gliomas. Our data demonstrate that two weeks of TMZ treatment at a clinically relevant dose of 25 mg/kg provides a significant survival advantage in WT-tumor-bearing mice, while no efficacy was observed in tumor-bearing mice with either heterozygous or homozygous loss of Msh2.
